Phase III Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab, Platinum-Based Chemotherapy, and Canakinumab in Advanced Non-Small Cell Lung Cancer
- Trial ID
- 2024-511490-29-00
- Protocol
- CACZ885U2301
- Sponsor
- Novartis Pharma AG
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this study is to determine the recommended phase 3 dose regimen (RP3R) of **canakinumab** in combination with **pembrolizumab** plus platinum-based doublet chemotherapy in the safety run-in part. Additionally, in the double-blind, randomized, placebo-controlled part, the study aims to compare progression-free survival (PFS) and overall survival (OS) between the two treatment arms in patients with locally advanced or metastatic non-squamous and squamous non-small cell lung cancer (NSCLC). These objectives are clinically relevant as they aim to optimize treatment regimens and improve survival outcomes for patients with NSCLC.
Secondary objectives include:
- Characterizing the pharmacokinetics (PK) and safety profile of canakinumab in combination with pembrolizumab plus platinum-based doublet chemotherapy.
- Assessing preliminary clinical anti-tumor activity, including overall response rate (ORR), disease control rate (DCR), and duration of response (DOR).
- Characterizing immunogenicity, specifically anti-drug antibodies (ADA) of canakinumab and pembrolizumab.
- Evaluating patient-reported outcomes (PROs) such as symptoms, physical functioning, and health-related quality of life.
Participants
The clinical trial involves a total of **347 participants** diagnosed with **non-small cell lung cancer**. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. Participants were selected based on specific criteria, including a histologically confirmed diagnosis of locally advanced or metastatic non-small cell lung cancer, measurable disease as per RECIST 1.1, and a known PD-L1 status. The trial also considers the **ECOG performance status**, requiring a score of 0 or 1. The population includes individuals from a vulnerable group, although specific lifestyle considerations such as diet or physical activity are not detailed. The selection process ensures a diverse representation of the affected population, adhering to the protocol-defined inclusion criteria.
Plans and Procedures
The clinical trial is designed as a **randomized, double-blind, placebo-controlled** phase III study to evaluate the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in subjects with locally advanced or metastatic **non-small cell lung cancer** (NSCLC). The trial aims to compare progression-free survival (PFS) and overall survival (OS) between the treatment arms. The study is expected to run from December 21, 2018, to June 7, 2027, with a maximum treatment period of 441 days for participants.
Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as histologically confirmed NSCLC, measurable disease by RECIST 1.1, known PD-L1 status, and an ECOG performance status of ≤ 1. Following the screening, eligible participants will be randomized into treatment groups. The trial includes a safety run-in part to determine the recommended phase 3 dose regimen of canakinumab, followed by the double-blind, randomized, placebo-controlled part.
Study visits will include regular follow-up assessments to monitor the incidence of dose-limiting toxicities, adverse events, and changes in laboratory values, vital signs, and ECGs. The primary endpoints focus on PFS and OS, while secondary endpoints include overall response rate (ORR), disease control rate (DCR), and duration of response (DOR) based on local investigator assessment. Participants will also be evaluated for the presence of anti-drug antibodies (ADA) and pharmacokinetic parameters of the investigational drugs.
The expected length of participant involvement is up to 441 days, with conditions for early termination including the occurrence of unacceptable toxicity, withdrawal of consent, or investigator decision based on the participant's best interest. The trial is not categorized as low intervention and is conducted under strict regulatory compliance to ensure the safety and well-being of all participants.
Treatment
The clinical trial involves the administration of **pemetrexed disodium**, a chemical compound used as an experimental medication. Pemetrexed disodium is provided in a pharmaceutical form identified as PHF00200MIG. The medication is administered intravenously, with a maximum daily dose of 500 mg/m² and a total maximum dose of 73,500 mg/m² over the treatment period. The treatment duration is set for a maximum of 441 days. The medication may be relabeled to include a study code or kit number, depending on local regulations and sourcing models. Participant compliance with the dosing schedule will be monitored throughout the trial.
Another experimental medication used in the trial is **canakinumab**, a protein-based substance classified as a solution for injection. Canakinumab is administered subcutaneously, with a maximum daily dose of 200 mg and a total maximum dose of 29,400 mg over the treatment period. The treatment duration is also set for a maximum of 441 days. The medication undergoes secondary repackaging and relabeling as part of the trial protocol. Compliance with the dosing schedule will be closely monitored to ensure adherence to the study requirements.
The trial is a randomized, double-blind, placebo-controlled, phase III study designed to evaluate the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy, with or without canakinumab, as a first-line therapy for subjects with locally advanced or metastatic non-squamous and squamous non-small cell lung cancer. The main objective is to determine the recommended phase 3 dose regimen of canakinumab in combination with pembrolizumab and to compare progression-free survival and overall survival between the treatment arms.
Efficacy
The efficacy of the clinical trial will be assessed through several primary and secondary endpoints. The primary endpoints include **Progression-Free Survival (PFS)** and **Overall Survival (OS)**, evaluated by local investigator assessment according to RECIST 1.1 criteria. These endpoints will be measured in the double-blind, randomized, placebo-controlled part of the study.
Secondary endpoints will further evaluate efficacy through various parameters. These include the Objective Response Rate (ORR), Disease Control Rate (DCR), Time to Response (TTR), and Duration of Response (DOR), all assessed by local investigators as per RECIST 1.1. Additionally, the study will monitor the frequency of adverse events, serious adverse events, and adverse events leading to treatment discontinuation. Laboratory abnormalities, ECG, and vital signs will also be recorded.
Pharmacokinetic (PK) parameters of canakinumab, pembrolizumab, and chemotherapy will be analyzed, alongside the prevalence and incidence of anti-drug antibodies (ADA) for canakinumab and pembrolizumab. Patient-reported outcomes (PROs) will be assessed using the QLQ-LC13 and QLQ-C30 questionnaires, focusing on symptom scores for chest pain, cough, dyspnea, global health status, shortness of breath, and pain.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Histologically confirmed locally advanced or metastatic NSCLC
- Measurable disease by RECIST 1.1
- Known PD-L1 status
- ECOG performance status (PS) ≤ 1.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria
- Previous immunotherapy or treatment with IL-1β inhibitor.
- Subjects with epidermal growth factor receptor (EGFR) sensitizing mutations and/or ALK rearrangement
- History of severe hypersensitivity reaction to monoclonal antibodies, platinum containing drugs, nab-paclitaxel, paclitaxel, pemetrexed or any known excipients of these drugs
- Other protocol-defined exclusion criteria may apply.
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Presence or history of a malignant disease, other than NSCLC, that has been diagnosed and/or required therapy within the past 3 years prior to randomization.
- Active autoimmune disease that has required systemic treatment in the past 2 years prior to randomization (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Control of the disorder with replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc) is permitted.
- History of (non-infectious) pneumonitis that required steroids or current pneumonitis.
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Germany | Not Recruiting | 21 Dec 2018 | 1 |
Spain | Not Recruiting | 21 Dec 2018 | 2 |
Sites & Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
CANAKINUMAB | Test | — | SUBCUTANEOUS USE | 200 | 441 | SUB30137 |
PEMETREXED | Other | PHF00200MIG | INTRAVENOUS USE | 500 | 441 | SCP11423984 |


